Literature DB >> 18490240

Mechanisms involved in Burkitt's tumor formation.

M R Campanero1.   

Abstract

Burkitt's lymphoma is a rapidly fatal tumor if untreated, but it is curable with intensive polychemotherapy. Unfortunately, the toxicities reported for its treatment in adults are poorly tolerated. Novel therapies aimed at specific molecular targets might prove to be less toxic. A better knowledge of the mechanisms involved in the pathogenesis of Burkitt's lymphoma would facilitate the identification of such targets. This review explores the current knowledge on the alterations found in the three main Burkitt's lymphoma variants.

Entities:  

Mesh:

Year:  2008        PMID: 18490240     DOI: 10.1007/s12094-008-0193-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  110 in total

Review 1.  Endemic Burkitt's lymphoma: a polymicrobial disease?

Authors:  Rosemary Rochford; Martin J Cannon; Ann M Moormann
Journal:  Nat Rev Microbiol       Date:  2005-02       Impact factor: 60.633

2.  Chromosome translocation and c-MYC activation by Epstein-Barr virus and Euphorbia tirucalli in B lymphocytes.

Authors:  T Aya; T Kinoshita; S Imai; S Koizumi; F Mizuno; T Osato; C Satoh; T Oikawa; N Kuzumaki; H Ohigashi
Journal:  Lancet       Date:  1991-05-18       Impact factor: 79.321

3.  Functional analysis of the p53 protein in AIDS-related non-Hodgkin's lymphomas and polymorphic lymphoproliferations.

Authors:  A Martin; J M Flaman; T Frebourg; F Davi; S El Mansouri; J Amouroux; M Raphaël
Journal:  Br J Haematol       Date:  1998-05       Impact factor: 6.998

4.  Epstein-Barr virus-enhancing plant promoters in east Africa.

Authors:  F Mizuno; T Osato; S Imai; S Koizumi; T Aya; T Kinoshita; N Hirai; M Hirota; H Ohigashi; K Koshimizu
Journal:  AIDS Res       Date:  1986-12

5.  Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors.

Authors:  C Cinti; P P Claudio; C M Howard; L M Neri; Y Fu; L Leoncini; G M Tosi; N M Maraldi; A Giordano
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

6.  Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

Authors:  Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  Solid cancers after bone marrow transplantation.

Authors:  R E Curtis; P A Rowlings; H J Deeg; D A Shriner; G Socíe; L B Travis; M M Horowitz; R P Witherspoon; R N Hoover; K A Sobocinski; J F Fraumeni; J D Boice
Journal:  N Engl J Med       Date:  1997-03-27       Impact factor: 91.245

8.  Epstein-Barr virus and Burkitt's lymphoma.

Authors:  I Magrath; V Jain; K Bhatia
Journal:  Semin Cancer Biol       Date:  1992-10       Impact factor: 15.707

9.  A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines.

Authors:  J Wiels; G M Lenoir; M Fellous; M Lipinski; J C Salomon; C Tetaud; T Tursz
Journal:  Int J Cancer       Date:  1982-06-15       Impact factor: 7.396

10.  Combined effect of the extracts from Croton tiglium, Euphorbia lathyris or Euphorbia tirucalli and n-butyrate on Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells.

Authors:  Y Ito; M Kawanishi; T Harayama; S Takabayashi
Journal:  Cancer Lett       Date:  1981-04       Impact factor: 8.679

View more
  1 in total

1.  E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma.

Authors:  Irene Molina-Privado; María Rodríguez-Martínez; Patricia Rebollo; Daniel Martín-Pérez; María-Jesús Artiga; Javier Menárguez; Erik K Flemington; Miguel A Piris; Miguel R Campanero
Journal:  Cancer Res       Date:  2009-05-01       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.